Set expectations Shedding from telogen effluvium usually peaks, then slows
Available from: Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Want to know if Semaglutide is right for you
The products were conceived and developed in collaboration with health and wellness experts Dr
While liraglutide also showed cardiovascular benefit (13% reduction in the LEADER trial), semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity
For instance, Medicare typically does not cover these drugs unless prescribed for another condition like diabetes